BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36313444)

  • 1. Identification of cuproptosis-related gene signature to predict prognosis in lung adenocarcinoma.
    Lv Y; Xiao Y; Cui X; Luo H; Xu L
    Front Genet; 2022; 13():1016871. PubMed ID: 36313444
    [No Abstract]   [Full Text] [Related]  

  • 2. The cuproptosis-related gene signature serves as a potential prognostic predictor for ovarian cancer using bioinformatics analysis.
    Sun X; Xu P; Zhang F; Sun T; Jiang H; Lu X; Zhang M; Li P
    Ann Transl Med; 2022 Sep; 10(18):1021. PubMed ID: 36267774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 4. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma.
    Wang Y; Zhang C; Ji C; Jin W; He X; Yu S; Guo R
    Front Genet; 2022; 13():1006938. PubMed ID: 36313439
    [No Abstract]   [Full Text] [Related]  

  • 7. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
    Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
    Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.
    Zhou J; Chen D; Zhang S; Wang C; Zhang L
    Front Genet; 2022; 13():1039983. PubMed ID: 36712848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and personalized treatment prediction in lung adenocarcinoma: An
    Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z
    Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011
    [No Abstract]   [Full Text] [Related]  

  • 11. Cuproptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of early-stage lung adenocarcinoma patients.
    Tang Y; Li Q; Zhang D; Ma Z; Yang J; Cui Y; Zhang A
    Front Genet; 2022; 13():977156. PubMed ID: 36186452
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA.
    Ling X; Zhang L; Fang C; Liang H; Zhu J; Ma J
    Transl Lung Cancer Res; 2023 Apr; 12(4):754-769. PubMed ID: 37197625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of the cuproptosis-related model to predict prognosis and indicate tumor immune infiltration in lung adenocarcinoma.
    Wu M; Bao J; Lei Y; Tao S; Lin Q; Chen L; Jin Y; Ding X; Yan Y; Han P
    Front Oncol; 2022; 12():935672. PubMed ID: 36338763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
    Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
    Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Cui Y; Zhang LJ; Xu YJ; Liu MY
    Am J Transl Res; 2023; 15(6):3942-3959. PubMed ID: 37434829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma.
    Wu G; Hu Q; Chen H; He M; Ma H; Zhou L; Xu K; Ren H; Qi J
    Front Oncol; 2023; 13():1127768. PubMed ID: 37007124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
    Li Z; Wang W; Wu J; Ye X
    Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cuproptosis-related gene in lung adenocarcinoma.
    Liu Y; Lin W; Yang Y; Shao J; Zhao H; Wang G; Shen A
    Front Oncol; 2022; 12():1080985. PubMed ID: 36620594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying machine learning algorithms to develop a survival prediction model for lung adenocarcinoma based on genes related to fatty acid metabolism.
    Cong D; Zhao Y; Zhang W; Li J; Bai Y
    Front Pharmacol; 2023; 14():1260742. PubMed ID: 37920207
    [No Abstract]   [Full Text] [Related]  

  • 20. Cuproptosis and Immune-Related Gene Signature Predicts Immunotherapy Response and Prognosis in Lung Adenocarcinoma.
    Sun Z; Chen X; Huang X; Wu Y; Shao L; Zhou S; Zheng Z; Lin Y; Chen S
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.